Analytical (technologies & services)

ADCs a big opportunity for Big Pharma say experts

Big Pharma business opportunities driving ADC boom say experts

By Gareth Macdonald

Big Pharma interest in antibody drug conjugates (ADC) hit another high this week with Roche  ,Novartis and AstraZeneca each announcing investments that boost their ability to develop and manufacture these small-molecule monoclonal antibody (mAb) drug...

Agilent is splitting into two companies

Agilent splits up to create two separate businesses

Agilent Technologies has officially separated its biopharma service offerings from its electric measurement group to create two separate companies, the life science portion of which is expected to bring in about $3.9B in FY2013.

New Melanoma Vaccine Tech Enters Ph I Trial

Harvard’s New Melanoma Vaccine Tech Enters Ph I Trial

By Zachary Brennan

A newly developed implantable melanoma vaccine is now in Phase I clinical trials thanks to the efforts of a cross-disciplinary team of engineers, scientists and clinicians from Harvard University and the Dana-Farber Cancer Institute.

Follow us

Product Innovations